

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/jtd-20-1776">http://dx.doi.org/10.21037/jtd-20-1776</a> .	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Data of subcarinal lymph node metastasis and other stations of lymph node metastasis I would like to share.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form and clinical study report will also be shared if request.
5	When will data availability begin?	From the publication date
6	When will data availability end?	One year within the publication date, since the 8 <sup>th</sup> AJCC staging system has already published and our study referred to 7 <sup>th</sup> AJCC staging system. Meanwhile, with the neoadjuvant therapy followed by surgery gradually become the standard protocol for esophageal cancer patients, more attention should be paid to subcarinal lymph node metastasis after neoadjuvant therapy.
7	To whom will you share the data?	Medical oncologists and thoracic surgeons.
8	For what type of analysis or purpose?	For analysis to evaluate the pattern of subcarinal lymph node metastasis in esophageal cancer, especially for contrasting with those after neoadjuvant therapy
9	How or where can the data/documents be obtained?	Emails could be sent to the address below: 450763473@qq.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.

